A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms.

@article{Botteman2004ACE,
  title={A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms.},
  author={Marc F. Botteman and Nisha P Shah and Jean Lian and Chris L. Pashos and J. Albert Simon},
  journal={Menopause},
  year={2004},
  volume={11 3},
  pages={343-55}
}
OBJECTIVES After the release of the results of the Women's Health Initiative, an emerging consensus suggests that continuous-combined hormone therapy (CCHT) should be limited to short-term management of moderate-to-severe vasomotor symptoms. This, in turn, raises the important question of the economic value, if any, of short-term CCHT for this indication. We conducted a cost-effectiveness analysis comparing a 1-year treatment course with 1 mg of norethindrone acetate/5 microg of ethinyl… CONTINUE READING
6 Citations
2 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-2 of 2 references

A cost - effectiveness evaluation of two continuous - combined hormone therapies for the management of moderate - to - severe vasomotor symptoms

  • JA Simon, JH Liu, L Speroff

Similar Papers

Loading similar papers…